The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice

Chronic kidney disease (CKD) affects around 10% of the global population and is most often caused by diabetes. Diabetes with CKD (diabetic kidney disease, DKD) is a progressive condition that may cause kidney failure and which contributes significantly to the excess morbidity and mortality in these...

Descripción completa

Detalles Bibliográficos
Autores principales: von Scholten, Bernt Johan, Kreiner, Frederik Flindt, Rasmussen, Søren, Rossing, Peter, Idorn, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Diabetic Kidney Disease: Pathogenesis and Therapeutic Targets
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301118/
https://www.ncbi.nlm.nih.gov/pubmed/35874312
http://dx.doi.org/10.1177/20420188221112490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301118/
https://www.ncbi.nlm.nih.gov/pubmed/35874312
http://dx.doi.org/10.1177/20420188221112490

Ejemplares similares